Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech), making it one of the largest healthcare companies globally. Investors research JNJ for its dividend history, defensive characteristics, and exposure to aging demographics and chronic disease treatment.
Get a full AI research report on JNJ
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Johnson & Johnson do?
JNJ generates revenue through two primary segments: Innovative Medicine, which develops and sells prescription drugs for oncology, immunology, neuroscience, and other therapeutic areas; and MedTech, which manufactures surgical instruments, orthopedic products, cardiovascular devices, and vision care solutions. Products are distributed through hospitals, wholesalers, retailers, and healthcare professionals worldwide. The company's business model relies on patent protection, brand strength, and recurring demand for both pharmaceutical treatments and medical devices.
Bull case
- ✓Strong gross margin of 68.1% and operating margin of 29.2% demonstrate pricing power and operational efficiency in a regulated industry.
- ✓Return on equity of 25.7% significantly exceeds typical S&P 500 averages, indicating effective capital deployment and profitability relative to shareholder equity.
- ✓Dividend yield of 2.0% with a payout ratio of 60.8% suggests sustainable income generation with room for potential growth, historically attractive to income-focused investors.
- ✓Diversified revenue streams across pharmaceuticals and medical devices reduce dependence on single product categories or therapeutic areas.
- ✓Forward P/E of 21.8x is notably lower than trailing P/E of 31.0x, potentially signaling market expectations for earnings growth ahead.
Bear case
- ✗Trailing P/E ratio of 31.0x is elevated relative to historical averages and broader market multiples, raising valuation concerns for value-oriented investors.
- ✗PEG ratio of 2.79 suggests the stock may be priced at a premium relative to expected earnings growth rates.
- ✗Debt-to-equity ratio of 57.7% indicates substantial leverage, which could constrain financial flexibility during economic downturns or if interest rates remain elevated.
- ✗Quick ratio of 0.725 is below 1.0, suggesting potential liquidity constraints in meeting short-term obligations without relying on inventory conversion.
- ✗Patent expirations on key drugs and generic competition pose ongoing revenue headwinds requiring continuous innovation and product pipeline success.
JNJ valuation & financial health
JNJ trades at a trailing P/E of 31.0x with a forward P/E of 21.8x, reflecting a valuation premium typical of large-cap healthcare leaders but elevated on absolute terms. The company demonstrates strong profitability with a net margin of 21.5% and ROE of 25.7%, though these metrics must be weighed against a PEG ratio of 2.79 and a debt-to-equity ratio of 57.7%. The current ratio of 1.089 and quick ratio of 0.725 indicate adequate but not exceptional liquidity. Enterprise value-to-EBITDA of 19.3x aligns with mature pharmaceutical peers, while the price-to-book ratio of 7.58x reflects investor expectations for continued earnings power and brand value.
The bottom line
Johnson & Johnson presents a classic large-cap healthcare profile: strong cash generation, defensive characteristics, and dividend income appeal offset by elevated valuation multiples and leverage. Key factors to weigh include the sustainability of earnings growth relative to current P/E levels, the company's ability to offset patent expirations through pipeline innovation, and macroeconomic sensitivity to healthcare spending. Investors should monitor quarterly earnings reports, pipeline progress on key drug candidates, and any changes to the dividend policy or debt management strategy.
Frequently asked questions
What does Johnson & Johnson do?
JNJ operates in two main segments: Innovative Medicine (prescription drugs for oncology, immunology, neuroscience, and other conditions) and MedTech (surgical instruments, orthopedic devices, cardiovascular products, and vision care). Products are sold globally to hospitals, healthcare professionals, and consumers.
Is JNJ a dividend stock?
Yes, JNJ pays a dividend with a current yield of 2.0% and a payout ratio of 60.8%, indicating the company distributes a meaningful portion of earnings while retaining capital for growth and debt service. The company has a long history of dividend payments and increases.
Is JNJ overvalued?
JNJ trades at a trailing P/E of 31.0x and a PEG ratio of 2.79, both elevated metrics that suggest a valuation premium. However, the forward P/E of 21.8x is notably lower, indicating market expectations for earnings growth. Valuation assessment depends on individual growth and discount rate assumptions.
What are the main risks for JNJ investors?
Key risks include patent expirations on major drugs, generic competition, high leverage (debt-to-equity of 57.7%), regulatory changes affecting drug pricing, and execution risk on the pharmaceutical pipeline. Economic slowdowns could also pressure healthcare spending.
How profitable is Johnson & Johnson?
JNJ demonstrates strong profitability with a net margin of 21.5%, gross margin of 68.1%, and operating margin of 29.2%. Return on equity of 25.7% indicates efficient use of shareholder capital, though these metrics should be evaluated alongside the company's leverage and capital structure.
What is JNJ's financial health?
JNJ has solid profitability and cash generation but carries substantial debt (debt-to-equity of 57.7%) and a quick ratio of 0.725, suggesting moderate liquidity. The company's strong operating margins and market position support debt servicing, though leverage limits financial flexibility.
Research JNJ with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.